In another example, atezolizumab, an antibody targeting programmed cell death protein 1, and bevacizumab, an antibody against vascular endothelial growth factor, are applied as combination therapy for unresectable hepatocellular carcinoma [9]. Here, PDCD1 is linked to hepatocellular carcinoma.